Prolactin receptor (PRLR), structurally homologous with growth hormone receptor, was reported to have a high level of expression in more than 80% of human breast cancer cells and tissues, and contribute to the development of breast cancer [8,11–13], which implicates PRLR could be used as a potential target for breast cancer treatment. Here, GHR is linked to breast carcinoma.